Precision Medicine for Hematological Malignancies

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 175

Special Issue Editors


E-Mail Website
Guest Editor
Department of Hematology and Medical Oncology, Emory University School of Medicine, Emory University, Atlanta, GA, USA
Interests: myeloid neoplasms; myeloproliferative neoplasms; chronic myeloid leukemia; myelodysplastic syndromes; myelodysplastic/myeloproliferative neoplasms; systemic mastocytosis; acute myeloid leukemia; molecular targeted therapies; risk stratification

E-Mail Website
Guest Editor
Department of Hematology and Medical Oncology, Emory University School of Medicine, Emory University, Atlanta, GA, USA
Interests: lymphoid neoplasms; Hodgkin lymphoma; non-Hodgkin lymphoma; chronic lymphocytic leukemia; hematopoietic stem cell transplant; immune effector cell therapy

Special Issue Information

Dear Colleagues,

The concept of personalized medicine is not new in the field of oncology, yet more progress has been made in the past decade than ever before. Advancements in sequencing technologies have led to better understanding of the molecular drivers of specific neoplasms and allowed for the widespread clinical application of genomic profiling of tumors, leading to the development and use of numerous targeted therapies. In addition, improved understanding of immunologic pathways has given way to a growing arsenal of immunotherapeutic agents, while the evaluation of large-scale datasets has allowed for the identification of specific subgroups of patients who benefit from unique therapeutic strategies.

The field of malignant hematology has been on the precipice of advancements in precision medicine. This Special Issue highlights cutting-edge research and clinical advances in myeloid malignancies, lymphoid neoplasms, plasma cell dyscrasias, and hematopoietic stem cell transplantation. The scope of topics in this Special Issue includes genomic profiling, targeted therapies, biomarker-driven treatment approaches, and novel immune targets and immunotherapeutic agents, as well as studies evaluating novel risk stratification and prognostic factors. Original research papers are encouraged; however, meta-analyses and topic reviews will also be considered for publication.

Dr. Anthony M. Hunter
Dr. Jason Romancik
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine
  • molecular targeted therapies
  • myeloid neoplasms
  • lymphoid neoplasms
  • plasma cell dyscrasias
  • hematopoietic stem cell transplantation
  • genomics
  • immunotherapies

Published Papers

This special issue is now open for submission.
Back to TopTop